Salute e Benessere

Preparative and Process Chromatography Market Worth $15.6 Billion |…

Browse in-depth TOC on "Preparative and Process Chromatography Market" Browse in-depth TOC on "Preparative and Process Chromatography Market" 195 - Tables 46 - Figures 261 - Pages Preparative and Process Chromatography Market Scope: Process chromatography segment is expected to account for the largest share in 2022. The preparative and process chromatography market, by type, has been segmented into process chromatography and preparative chromatography. In 2022,...
PR Newswire
03/11/2023

Verismo Therapeutics Announces Upcoming Presentation at SITC 2023

Title: Preclinical potency assessment of SynKIR-110, a mesothelin-specific KIR-CAR T cell therapy for mesotheliomaAbstract Number: 321Date and Time: Friday, November 3rd: 12:00-1:30 p.m. and 5:10-6:40 p.m.Presenting Authors: Dr. Jun Xu, PhD & Dr. Laura Johnson, PhDDescription: We conducted in vivo potency studies to assess the impact of the engineered T cell dose of the first mesothelin (MSLN)-specific KIR-CAR T cell therapy (SynKIRTM-110) in an NSG mouse xenograft model of human…
PR Newswire
03/11/2023

Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational…

Cash position stands at $40.0 million with a projected cash runway through critical milestones, including BRACELET-1 survival data Cash position stands at$40.0 millionwith a projected cash runway through critical milestones, including BRACELET-1 survival data Management hosting conference call and webcast today at8:30 a.m. ET SAN DIEGOandCALGARY, AB,Nov. 3, 2023/PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics...
PR Newswire
03/11/2023

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate…

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateResults from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE Phase 1b/2 study on track for H1 2024ACI-24.060 ABATE interim safety and immunogenicity data in Alzheimer's disease (AD) expected by year-endACI-7104.056 alpha-synuclein active immunotherapy in Phase 2 'VacSYn' Parkinson's disease (PD) trial to complete Cohort 1 enrollment and report...
Nasdaq GlobeNewswire
03/11/2023

Global Blood Glucose Monitoring Device Market Poised for Remarkable Growth, Set…

Empowering Individuals with Diabetes Empowering Individuals with Diabetes The blood glucose monitoring device market is dedicated to producing and supplying devices and products designed to monitor and manage blood glucose levels, primarily catering to individuals with diabetes. These tools play a crucial role in enabling individuals with diabetes to monitor their blood sugar levels, thereby empowering them to make informed decisions regarding their diet, medication, and lifestyle...
PR Newswire
03/11/2023

Global Injectable Drug Delivery Market Projected to Reach USD 58.90 Billion by…

Unlocking the Potential of Injectable Drug Delivery Unlocking the Potential of Injectable Drug Delivery Injectable drug delivery, involving the direct administration of medications through needles or similar devices, presents a host of advantages. These include precise and controlled drug delivery to different body areas, rapid onset of action, enhanced bioavailability, and bypassing the digestive system. The most significant breakthrough is the role injectable drug delivery plays in...
PR Newswire
03/11/2023

Global Thyroid Gland Disorder Treatment Market Set to Reach USD 3.15 Billion by…

Advancing Thyroid Gland Disorder Treatment Advancing Thyroid Gland Disorder Treatment The thyroid gland disorder treatment market encompasses the production, distribution, and sale of products and services aimed at addressing various thyroid gland-related medical conditions. This market primarily includes pharmaceuticals, diagnostic tools, and therapeutic procedures, catering to patients with conditions like hypothyroidism, hyperthyroidism, goiter, and thyroid cancer. Key components of...
PR Newswire
03/11/2023

The Sixth CIIE is ready to welcome the world

This year's Business Exhibition will feature 289 of the world's top 500 enterprises and industry giants, including the world's top 15 automotive brands, top 10 industrial electrical companies, top 10 medical device companies, three major mining giants, four major grain traders and five major shipping companies. Some 1,500 small and medium-sized enterprises (SMEs) will also be showcasing their products at the event. This year's Business Exhibition will feature 289 of the world's top 500...
PR Newswire
03/11/2023

Pierre Fabre Laboratories to accelerate their development in onco-hematology by…

This strategic acquisition enables Pierre Fabre Laboratories to gain a foothold in the United States in the field of oncology This strategic acquisition enables Pierre Fabre Laboratories to gain a foothold inthe United Statesin the field of oncology CASTRES,France,Nov. 3, 2023/PRNewswire/ -- Pierre Fabre Laboratories announced today an expanded global partnership with Atara Biotherapeutics, a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus...
PR Newswire
03/11/2023

iOnctura to present research on roginolisib and IOA-359 at ASH

Details of the presentations are as follow: Details of the presentations are as follow: Presentation Title: Novel PI3Kδ Inhibitor Roginolisib Synergizes with the Bcl-2 Inhibitor Venetoclax in Hematological Malignancies Session Name: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III Session Date:Monday, December 11, 2023 Presentation Time:6:00 PM - 8:00 PM Presenter:Dr. Kandathilparambil SasiLocation:San DiegoConvention Center, Halls...
PR Newswire
03/11/2023

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT OCTOBER 2023

Accumulated revenue for January - October 2023 increased by 22 % to SEK 1400.5 (1147.2) million. Accumulated revenue for January -October 2023increased by 22 % toSEK 1400.5(1147.2) million. Revenues were distributed as follows: Countries in regions: -The Nordics:Denmark, Faroe Island,Finland,Iceland,Norway,Sweden- Central Europe :Austria,Germany,Switzerland- East Europe :Czech Republic,Slovakia,Hungary,Poland,Romania-South &...
PR Newswire
03/11/2023

Bioservo Technologies: Carbonhand sales doubled in Norway

So far this year, Bioservo has received orders for 27 Carbonhand at an order value of about SEK 1.8 million. These have been ordered for patients suffering from stroke, MS, and other neurological diseases. So far this year, Bioservo has received orders for 27 Carbonhand at an order value of aboutSEK 1.8 million. These have been ordered for patients suffering from stroke, MS, and other neurological diseases. "As the new version of Carbonhand becomes known to therapists and patients...
PR Newswire
03/11/2023

Joe Ryan to retire as Medicover Chief Financial Officer in 2024

For further information, please contact: For further information, please contact: Hanna Bjellquist, Head of Investor Relations +46 703 033 272hanna.bjellquist@medicover.com Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities, laboratories and blood-drawing points and the largest markets arePoland,Germany,RomaniaandIndia...
PR Newswire
03/11/2023

Medicover: Interim report July-September 2023

Nine months Nine months REVENUE AND EARNINGS Definition and reconciliation of alternative performance measures are available atwww.medicover.com/financial-information.1) 2022 is restated for IFRS 17Insurance contracts. For further information, refer to note 1.2) LTM: last twelve months (1 October 2022-30 September 2023). CEO Statement We are continuing to follow our road map and are delivering according to plan. We are delivering strong organic growth and have...
PR Newswire
03/11/2023

Nexstim Plc: Share subscriptions based on stock options 2020A

Company Announcement, Helsinki, 3 November 2023 at 9:30 AM (EET) Nexstim Plc: Share subscriptions based on stock options 2020A Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that between 1 April and 2 October 2023, a total of 1,000 Nexstim Plc's new shares has been subscribed for with the company's stock options 2020A. For subscriptions made with the stock options 2020A, the entire subscription price of EUR 2,000.00 will be entered in the reserve for invested…
Nasdaq GlobeNewswire
03/11/2023

Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS…

Press Release Stockholm, Sweden, November 3, 2023 Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients published in peer-reviewed medical journalPublication provides additional clinical evidence that vididencel has strong potential as a new maintenance therapy in AML and high-risk MDS patientsPatients with low disease burden have the best chance to respond to vididencel treatment, supporting the maintenance therapy setting currently pursued in the...
Nasdaq GlobeNewswire
03/11/2023

The 2nd Boao International Conference on Real World Studies of Medical Products…

It's worth noting that the National Medical Products Administration and the Hainan provincial government jointly initiated a pilot project for the application of clinical real-world data in June 2019. In the meantime, the Hainan Boao Lecheng International Medical Tourism Pilot Zone (Lecheng Pilot Zone) has been actively collecting real-world evidences and researching to explore how to assist the regulatory decision-making, offering new methods for the reform of the national evaluation system of…
PR Newswire
03/11/2023

GENFIT to Present Update on Scientific and Corporate Progress at The Liver…

GENFIT to lead 3 key events on ACLF during AASLD:ACLF Day for Investors/Analysts on November 11, 2023Patient Advocacy Council meeting on November 11, 2023ACLF Investigator event on November 12, 2023Detailed interim data from the ELATIVE ®Phase 3 results evaluating elafibranor in PBC to be presented by GENFIT's partner Ipsen, in a late breaking oral session on November 13, 2023GENFIT to present new data on its NASH 1diagnostics technology Lille (France),...
Nasdaq GlobeNewswire
02/11/2023

Sarcoidosis Market to Register Incremental Growth During the Forecast Period…

Key Takeaways from the Sarcoidosis Market Report Discover which therapies are expected to grab the major sarcoidosis market share @Sarcoidosis Market Report Sarcoidosis Overview Sarcoidosis, an enigmatic systemic condition, is characterized by the formation of immune granulomas in various organs, primarily affecting the lungs and the lymphatic system. Despite its prevalence, the root cause of sarcoidosis remains unidentified, making diagnosis challenging and often...
PR Newswire
02/11/2023

DBV Technologies to Present New Data at ACAAI 2023

DBV Technologies to Present New Data at ACAAI 2023 New data to include late-breaking abstract detailing interim 12-month results from the ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) of Viaskin™ Peanut in peanut-allergic toddlers.DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new data on the use of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic toddlers...
Nasdaq GlobeNewswire
02/11/2023

Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of…

/r NHL) and updated results of the Phase I BALLI-01 clinical trial evaluating UCART22 in patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia, (r/r B-ALL) will be presented at the American Society of Hematology 65 thAnnual Meeting (ASH 2023), that will take place on December 9-12, 2023 in San Diego (CA) and online. These data will be presented in two poster sessions:Poster Presentation (P2110) Title: Preliminary Results of Nathali-01: A First-in-Human...
Nasdaq GlobeNewswire
02/11/2023

Theriva™ Biologics to Participate in the BIO-Europe Conference

BIO-Europe ConferenceFormat: Corporate presentation and one-on-one meetings Presentation Date: Tuesday, November 7, 2023 Presentation Time: 11:15am CET About Theriva™ Biologics, Inc. Theriva ™Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company's wholly-owned Spanish subsidiary Theriva Biologics, S.L., has been developing a new oncolytic adenovirus...
Nasdaq GlobeNewswire
02/11/2023

Galapagos reports third quarter 2023 results and releases new encouraging data…

First nine months 2023 key financials:Group revenues of €448.9 million Jyseleca® net sales of €82.1 million Cash and current financial investments of €3.8 billion at 30 September 2023Full year 2023 net Jyseleca® sales guidance of €100-€120 million and cash burn guidance of €380-€420 million reiterated Jyseleca® strategic evaluation completed: signed Letter of Intent to transfer the Jyseleca® (filgotinib) business to Alfasigma, including the European and UK Marketing...
Nasdaq GlobeNewswire
02/11/2023

BBS-Bioactive Bone Substitutes – Insider information: The company provides an…

BBS-Bioactive Bone Substitutes Plc, Company announcement, insider information, 2 November 2023 at 19.30 EETBBS-Bioactive Bone Substitutes – The company provides an update on the CE marking process related to the approval of the quality system – consultation with the Finnish Medicines Agency to begin on 21 November 2023 BBS-Bioactive Bone Substitutes Plc ("BBS") has been informed by the Notified Body on 2 November 2023 that the final approval of the quality system is expected within...
Nasdaq GlobeNewswire
02/11/2023
Altri  Comunicati